No Data
No Data
No Data
No Data
No Data
Express News | Lumos Pharma Announces Abstracts Reviewing Data From Its Phase 2 OraGrowth210 And OraGrowth212 Trials Will Be Presented At Upcoming Medical Meetings
Moomoo 24/7Apr 18 16:08 ET
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
GlobeNewswireApr 18 16:05 ET
Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes
TipRanksMar 20 11:45 ET
Express News | Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
Moomoo 24/7Mar 20 08:06 ET
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 10 08:31 ET
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 8 14:06 ET
No Data
No Data